Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Last year, The experimental drug KarXT, developed by Karuna Therapeutics, is expected to receive FDA approval later this month (Sept. 26), marking a significant breakthrough in schizophrenia treatment.
由karuna therapeutics開發的實驗藥物KarXt預計將於本月後期（9月26日）獲得FDA批准，這標誌着精神分裂症治療方面的重要突破。
If approved, KarXT would become the first novel schizophrenia drug in over 70 years, offering new hope for patients and medical professionals alike.
如果獲得批准，KarXt將成爲70年來首個新型精神分裂症藥物，爲患者和醫務人員帶來新的希望。
Schizophrenia, a mental disorder that affects approximately 3.8 million adults in the U.S., is often characterized by severe symptoms such as social isolation, memory issues and psychotic episodes.
精神分裂症是一種影響美國約380萬成年人的精神障礙，常以社交隔離、記憶問題和幻覺發作等嚴重症狀爲特徵。
Last year, Bristol-Myers Squibb & Co (NYSE:BMY) acquired Karuna Therapeutics for $330 per share in cash for a total equity value of $14 billion, or $12.7 billion net of estimated cash acquired.
去年，百時美施貴寶（紐交所：BMY）以每股330美元的現金收購了Karuna Therapeutics，總權益價值爲140億美元，或考慮到預計現金收購後淨額爲127億美元。
The Financial Times highlights that existing treatments, mainly focused on blocking dopamine receptors, often come with serious side effects, including weight gain and involuntary movements.
《金融時報》指出，現有的治療方案主要集中在阻斷多巴胺受體上，往往伴隨嚴重副作用，包括體重增加和不自主運動。
Despite the enthusiasm surrounding KarXT, the complexity and financial constraints of the U.S. health care system could limit access to this new treatment.
儘管圍繞KarXt存在着熱情，但美國醫療保健系統的複雜性和財政限制可能限制對這種新治療的獲取。
High drug pricing could also hinder access; the Institute for Clinical and Economic Review has suggested KarXT be priced at up to $20,000 per year.
高昂的藥品定價也可能阻礙獲取；臨床與經濟評估研究所建議，KarXt的定價可達每年最多2萬美元。
In August, AbbVie Inc (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics, another company focused on developing drugs for neurological disorders, for a total equity value of approximately $8.7 billion, or $45 per share in cash.
今年8月，艾伯維公司（紐交所：ABBV）完成了對Cerevel Therapeutics的收購，後者是另一家專注於研發神經疾病藥物的公司，總權益價值約爲87億美元，或每股現金45美元。
The challenges extend beyond the cost and availability of medications, the Financial Times report adds. Many individuals with mental health conditions, particularly schizophrenia, encounter law enforcement rather than health care professionals during crises.
挑戰不僅僅在於藥物的成本和可獲性，據《金融時報》報道。許多患有精神疾病，特別是精神分裂症的個人，在危機期間遇到執法人員，而非醫護人員。
While KarXT's approval could represent a crucial step forward, many experts, including Michael Thompson, a criminal justice expert, say that more systemic changes are needed to ensure mental health care is accessible and effective, especially for vulnerable populations like the homeless, according to FT.
儘管KarXT的批准可能代表着一個重要的進步，但許多專家，包括刑事司法專家邁克爾·湯普森（Michael Thompson）表示，爲了確保精神康復治療的可及性和有效性，特別是對於像無家可歸者這樣的弱勢人群，更需要進行系統性的改變。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
- Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
- Zevra Therapeutics的藥物成爲首個獲得FDA批准用於超稀有神經退行性疾病的治療
Photo via Pixabay.
圖片來自Pixabay。
譯文內容由第三人軟體翻譯。